Amgen

Open: 323.64 Close: 323.19 Change: -0.45

9 lessons that an AI found about Amgen Company Inc Stock after reading internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, year, drug, Inc, stock, day, and the most common words in the summary are: amgen, stock, market, top, price, job, inc, . One of the sentences in the summary was: Over the past month, shares of Amgen have returned +4.5% versus the Zacks S&P …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Over the past month, shares of Amgen have returned +4.5% versus the Zacks S&P 500 composites +1.6% change. Amgen revenue increased by just 4% year over year in the third quarter.

Today's News

Amgen Inc. stock outperforms competitors despite losses on the day - marketwatch.com. Over the past month, shares of Amgen have returned +4.5% versus the Zacks S&P 500 composites +1.6% change. Amgen revenue increased by just 4% year over year to $6.9 billion in the third quarter. Between Tepezza and Horizon Therapeutics pipeline, Amgen hopes to find its next blockbuster. Amgen v. Sanofi is a United States Supreme Court case in which the Court held that Amgens two patent applications on cholesterol-lower drugs failed to satisfy the enablement clause of the Patent Act. Amgen is an Equal Opportunity Employer. Amgen has failed to enable all that it has claimed, even allowing for a reasonable degree of experimentation. In other words, Amgen did not provide adequate details for an expert in the field. Amgen announces webcast of 2023 fourth quarter and full year financial results. Amgen is a leader in biotechnology-based human therapeutics. ETC-1002 may not be as effective as the PCSK9 drugs, including the newly-approved Praluent from Regeneron ($REGN) and Sanofi ($SNY) as well as a rival Amgen ($AMGN) drug, it also has a shot at grabbing a significant share. Amgen stock (NASdaq:amgn), quotes and news summary - benzinga.com: 2.586M / 2.397M Mkt Cap 172.970B day range 320.750 - 325.775 52 Wk Range 211.710 - 324.820. The next Amgen (AMGN) dividend date is projected to be February 15, 2024. There is no upcoming split for Amgen. Amgen expanded its work with AWS to create generative artificial intelligence (generative AI)–based solutions, using Amazon SageMaker to help discover, develop, and accelerate the manufacturing of medicines. Amgen Inc expected to post earnings of $4.60 a share - Earnings Preview. Wall Streets median 12-month price target for Amgen is $313.50​, below​ its last closing price of $324.56.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, year, drug, Inc, stock, day, and the most common words in the summary are: amgen, stock, market, top, price, job, inc, . One of the sentences in the summary was: Over the past month, shares of Amgen have returned +4.5% versus the Zacks S&P 500 composites +1.6% change. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #top #price #job #inc.